Inhaled nitric oxide (NO) is a selective pulmonary vasodilator effective in treating persistent pulmonary hypertension in newborns and in infants following congenital heart disease surgery. Recently, multiple in vivo and in vitro studies have shown a negative effect of NO on surfactant activity as well as surfactant protein gene expression. Although the relationship between NO and surfactant has been studied previously, the data has been hard to interpret due to the model systems used. The objective of the current study was to characterize the effect of NO on surfactant protein gene expression in primary rat type II pneumocytes cultured on a substratum that promoted the maintenance of type II cell phenotype. Exposure to a NO donor, S-nitroso-N-acetylpenicillamine (SNAP), decreased surfactant protein (SP)-A, (SP)-B, and (SP)-C mRNA levels in type II pneumocytes in a time-and dose-dependent manner. The effect was mediated in part by an increase in endothelin-1 secretion and a decrease in the intracellular messenger, phosphorylated ERK1/2 mitogen-activated protein kinases (MAPK). Exposing type II pneumocytes to endothelin-1 receptor antagonists PD-156707 or bosentan before exposure to SNAP partially prevented the decrease in surfactant protein gene expression. The results showed that NO mediated the decrease in surfactant protein gene expression at least in part through an increase in endothelin-1 secretion and a decrease in phosphorylated ERK1/2 MAPKs. extracellular signal-regulated kinase 1/2; endothelin-1 INHALED NITRIC OXIDE (NO) is a selective pulmonary vasodilator effective in treating elevated pulmonary vascular resistance in newborns with persistent pulmonary hypertension (10, 50) and in children with pulmonary hypertension following congenital heart disease (CHD) surgery (8, 43). However, multiple in vivo and in vitro studies have shown a negative effect of NO on surfactant activity as well as surfactant protein gene expression (26,58). In children with elevated pulmonary vascular resistance, any decrease in pulmonary compliance due to low surfactant activity can contribute to significant morbidity (13,31). Although the relationship between NO and surfactant has been studied, the model systems used previously included primary cultures that immediately begin to undergo dedifferentiation, whole animals, and alveolar epithelial cell lines that do not express the entire type II cell phenotype.Previous experiments exploring the role of NO on surfactant synthesis, secretion, and/or metabolism have focused on the role of toxic intermediates of NO such as peroxynitrite (25-26, 28, 42, 61), methemoglobin (29 -30, 32), and nitrogen dioxide (NO 2 ) (45). In vitro, peroxynitrite has been shown to decrease surfactant surface activity through lipid peroxidation and nitration of tyrosine residues on surfactant protein (SP)-A and SP-B (25-26, 28, 42, 61). Haddad et al. (27) also have shown that, in freshly isolated adult rat type II cells, several NO donors decreased the rate of surfactant synthesis as measured by the ...